SCM
KPTI icon

Symons Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Symons Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,451
Closed -$225K – 74
2021
Q2 		$225K Sell
1,451
-8
-0.5% -$1.16K 0.13% 64
2021
Q1 		$230K Buy
+1,459
New +$307K 0.12% 72

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Symons Capital Management's KPTI Position: Q3 2021 in Review

Symons Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 1,451 shares — an estimated $225K sold.

Symons Capital Management first reported a position in KPTI in Q1 2021 and held it in 2 quarters. The position peaked at $230K in Q1 2021. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

  • Symons Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Symons Capital Management sold 1,451 Karyopharm Therapeutics shares in Q3 2021, an estimated $225K.
  • Symons Capital Management first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 2 quarters.
  • Symons Capital Management's Karyopharm Therapeutics position peaked at $230K in Q1 2021.
  • 134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Symons Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.